April 6, 2017
Hikma, Jazz settle for Xyrem patent litigation
Hikma Pharmaceuticals and Jazz Pharmaceuticals have found a mutual language regarding a Jazz’s Xyrem patent litigation.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
April 5, 2017
Allecra Therapeutics appoints new Chairman of the Board and CMO
Allecra Therapeutics, a Germany-based clinical-stage biopharmaceutical company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections, has appointed Dr. Engelbert (Bert) Tjeenk Willink as a Chairman of the Board and Dr. Leon Hooftmanas as Chief Medical Officer.
April 5, 2017
Sanofi welcomes new EVP
Sanofi has appointed Bill Sibold, a current head of Sanofi Genzyme’s Global Multiple Sclerosis, Oncology and Immunology organization, as Executive Vice President Sanofi Genzyme and member of the Executive Committee, effective July 1, 2017.
April 5, 2017
Heptares trigers milestone payment from AstraZeneca
Sosei Group Corporation’s subsidiary Heptares Therapeutics got milestone payment from AstraZeneca for working together on an immuno-oncology project.
April 5, 2017
Abzena raises £25 M to boost its growth
Abzena, a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, will initiate a placing to raise approximately £25 million to expand further its service offering, capacity and capabilities.
April 5, 2017
Sanofi’s partner JHL Biotech accepted for clinical trial in China
JHL Biotech said Wednesday its Clinical Trial Application (CTA) for use of its first product in pipleine, JHL1101 in Phase 1 and Phase 3 clinical trials in Non-Hodgkin’s Lymphoma patients has been accepted by the China Food and Drug Administration (CFDA).
April 5, 2017
BD buys Israel’s CME
BD (Becton, Dickinson and Company), a medical technology company, has completed the acquisition of Israeli-based Caesarea Medical Electronics (CME), a global infusion pump systems manufacturer.
April 5, 2017
Radiopharmaceuticals market could double up in 4 years
According to the report, the global market radiopharmaceuticals were valued at nearly $5.1 billion and $5.7 billion in 2014 and 2015, respectively.
April 4, 2017
FDA will look into Janssen’s sNDA for ibrutinib
The U.S. FDA will review a supplemental New Drug Application for Janssen’s Imbruvica for chronic graft-versus-host-disease after failed certain therapies.
April 4, 2017
Cannabics Pharmaceuticals gets final report of its research on antitumor properties of cannabinoids in Israel
Cannabics Pharmaceuticals has received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity of cannabinoids was reflected in several types of cancer.